Clinical significance of correcting the serum level of phenytoin according to the albuminaemia in hospitalized patients and outpatients;Significación clínica de la corrección del nivel sérico de fenitoína en función de la albuminemia en pacientes hospitalizados y ambulatorios

Revista de Neurologia

Volumn 37, Issue 10, 2003, Pages 909-912

  Hermida Ameijeiras, J ^a   Montero Furelos, C ^a   Tutor Valcarce, J C ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Albumin; Phenytoin; Sheiner Tozer equation

Indexed keywords

PHENYTOIN; SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HOSPITAL PATIENT; HUMAN; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; OUTPATIENT; STANDARDIZATION;

EID: 0345168890     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3710.2003050     Document Type: Article

References (18)

1. Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med 2002; 40: 986-93.
2. Kwong TC. Free drug measurements: methodology and clinical significance. Clin Chim Acta 1985; 151: 193-216.
3. Soldin SJ. Free drug measurements. When and why? An overview. Arch Pathol Lab Med 1999; 123: 822-3.
4. Winter ME. Farmacocinética clínica básica. 2 ed. Madrid: Díaz de Santos; 1994. p. 259-61.
5. Dager WE, Inciardi JF, Howe TL. Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia. Ann Pharmacother 1995; 29: 667-70.
6. Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit 2002; 24: 379-85.
7. Jiménez-Torres NV, Casabó-Alós VG, Sancho-Chust V. Manual de procedimientos para farmacocinética clínica. Valencia: Fundación para el Desarrollo Clínico de la Farmacia; 1997. p. 12-3.
8. Herbeth B. Albumine. In Siest G, Henny J, Schiele F, eds. Références en biologie clinique. Amsterdam: Elsevier; 1990. p. 93-106.
9. Harris EK. Proposed goals for analytical precision and accuracy in single-point diagnostic-testing. Theoretical basis and comparison with data from College of American Pathologists Proficiency Surveys. Arch Pathol Lab Med 1988; 112: 416-20.
10. Knoll E, Hafner F, Dettmer K, Wisser H. The determination of calcium, urea and uric acid using the Kodak Ektachem multilayer technology: an evaluation. J Clin Chem Clin Biochem 1982; 20: 491-9.
11. Painter PC, Cope JY, Smith JL. Reference information for the Clinical Laboratory. In Burtis CA, Ashwood ER, eds. Tietz fundamentals of clinical chemistry. Philadelphia: WB Saunders Company; 2001. p. 955-1028.
12. Fedler C, Stewart MJ. Plasma total phenytoin: a possibly misleading test in developing countries. Ther Drug Monit 1999; 21: 155-60.
13. Crowder KM. An algorithm for monitoring phenytoin therapy. J Am Acad Nurse Pract 2002; 12: 317-21.
14. Rowland M. Plasma protein binding and therapeutic drug monitoring. Ther Drug Monit 1980; 2: 29-37.
15. Monaghan MS, Marx MA, Olsen KM, Turner PD, Bergman KL. Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation. Ther Drug Monit 2001; 23: 263-7.
16. Anderson GD, Pak C, Doane KW, Griffy KG, Tenkin NR, Wilensky AJ, et al. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother 1997; 31: 279-84.
17. Danhof M, Breimer DD. Therapeutic drug monitoring in saliva. Clin Pharmacokin 1978; 3: 39-57.
18. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokin 1999; 36: 453-70.